Article Text

other Versions

PDF
Original article
Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome
  1. Guilherme Lopes Yamamoto1,2,
  2. Meire Aguena2,
  3. Monika Gos3,
  4. Christina Hung4,
  5. Jacek Pilch5,
  6. Somayyeh Fahiminiya6,
  7. Anna Abramowicz3,
  8. Ingrid Cristian7,
  9. Michelle Buscarilli1,
  10. Michel Satya Naslavsky2,
  11. Alexsandra C Malaquias8,
  12. Mayana Zatz2,
  13. Olaf Bodamer4,
  14. Jacek Majewski6,
  15. Alexander A L Jorge8,
  16. Alexandre C Pereira9,
  17. Chong Ae Kim1,
  18. Maria Rita Passos-Bueno2,
  19. Débora Romeo Bertola1,2
  1. 1Unidade de Genética, Instituto da Criança, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil
  2. 2Centro de Pesquisa sobre o Genoma Humano e Células-Tronco, Instituto de Biociências da Universidade de São Paulo, São Paulo, São Paulo, Brazil
  3. 3Department of Medical Genetics, Institute of Mother and Child, Warsaw, Poland
  4. 4Division of Genetics and Genomics, Department of Medicine, Boston Children's Hospital, Boston, Massachusetts, USA
  5. 5Department of Child Neurology, Medical University of Silesia, Katowice, Poland
  6. 6Department of Human Genetics, McGill University, Montreal, Quebec, Canada
  7. 7Nemours Children's Hospital Orlando, Orlando, Florida, USA
  8. 8Departamento de Endocrinologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil
  9. 9Instituto de Cardiologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil
  1. Correspondence to Dr Débora Romeo Bertola, Unidade de Genética, Instituto da Criança do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Enéas Carvalho de Aguiar, 647, São Paulo, SP CEP 05403-000, Brazil; debora.bertola{at}usp.br

Abstract

Background Noonan syndrome is an autosomal dominant, multisystemic disorder caused by dysregulation of the RAS/mitogen activated protein kinase (MAPK) pathway. Heterozygous, pathogenic variants in 11 known genes account for approximately 80% of cases. The identification of novel genes associated with Noonan syndrome has become increasingly challenging, since they might be responsible for very small fractions of the cases.

Methods A cohort of 50 Brazilian probands negative for pathogenic variants in the known genes associated with Noonan syndrome was tested through whole-exome sequencing along with the relatives in the familial cases. Families from the USA and Poland with mutations in the newly identified genes were included subsequently.

Results We identified rare, segregating or de novo missense variants in SOS2 and LZTR1 in 4% and 8%, respectively, of the 50 Brazilian probands. SOS2 and LZTR1 variants were also found to segregate in one American and one Polish family. Notably, SOS2 variants were identified in patients with marked ectodermal involvement, similar to patients with SOS1 mutations.

Conclusions We identified two novel genes, SOS2 and LZTR1, associated with Noonan syndrome, thereby expanding the molecular spectrum of RASopathies. Mutations in these genes are responsible for approximately 3% of all patients with Noonan syndrome. While SOS2 is a natural candidate, because of its homology with SOS1, the functional role of LZTR1 in the RAS/MAPK pathway is not known, and it could not have been identified without the large pedigrees. Additional functional studies are needed to elucidate the role of LZTR1 in RAS/MAPK signalling and in the pathogenesis of Noonan syndrome.

  • Noonan Syndrome
  • LZTR1
  • SOS2
  • High-Throughput Nucleotide Sequencing
  • Rasopathies

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.